Global Canine Atopic Dermatitis Market Size, Trends, and Analysis- Forecasts To 2026 By Product (Glucocorticoids, Antihistamines, Immunosuppressants, MAbs, Others), By Mode of Administration (Topical, Oral, Injectable), By Distribution Channel (Veterinary Hospitals/Clinics, Retail, E-commerce), By Region (North America, Asia Pacific, CSA, Europe, and the Middle East and Africa); End-User Landscape, Company Market Share Analysis & Competitor Analysis
Canine Atopic dermatitis is a skin condition that causes allergic reactions when the dog is exposed to allergens like pollen, mites, and dust. These animals are not able to protect themselves or have the capability to fight against this disease or from any other allergens. Excessive scratching, foul odor, hair loss, scraping against the carpet, itching, and scaly skin are all typical symptoms of this disorder. However, as the dogs' skin grows more fragile over time, they struggle even more as they grow atopy. Allergic reactions are more common in dogs than in other pets. While many species can develop canine atopic dermatitis, Dalmatians, Beagles, Shar-Peis, Boxers, Bulldogs, Retrievers, and Irish Setters are the breeds most commonly affected. Canine atopic dermatitis is becoming more common each year, as per the veterinarians.
The most important factor behind the global canine atopic dermatitis treatment market's accelerated growth is the increasing prevalence of canine atopic dermatitis around the globe. Ignorance of canine atopic dermatitis' allergic conditions can lead to the growth of the canine atopic dermatitis treatment market. However, many factors such as drug side effects such as extreme allergic reactions in dogs, and poor management of canine atopic dermatitis may stymie demand growth over the coming years. An immunotherapeutic for canine atopic dermatitis is now being developed to further reduce the clinical symptoms of atopic dermatitis in dogs. For various weeks, Canine Atopic Dermatitis immunotherapeutic remains in circulation. In a laboratory safety analysis involving 7 successive monthly subcutaneous injections, the Canine Atopic Dermatitis immunotherapeutic was also shown to be well tolerated in dogs. In the near future, the acceptance and launching of a Canine Atopic Dermatitis immunotherapeutic could propel the Canine Atopic Dermatitis care market forward. One of the main factors boosting demand for this sector is the growing number of veterinarians. Additionally, rising Research & Development spending by key market participants, product releases, and a robust drug pipeline is projected to substantially contribute to market growth.
During the forecast period, increasing demand for pet insurance and increased concern among pet owners are expected to have a positive effect on the market. Furthermore, the Food and Drug Administration (FDA) and other regulatory agencies are enforcing strict rules to limit off-label use of human drugs in animals, which is fuelling demand growth.
The canine atopic dermatitis treatment market has been classified into antihistamines, MAbs, immunosuppressants, glucocorticoids, and others depending on the product. Because of their greater use and lower cost, glucocorticoids led the market in terms of sales in 2020. Oral and topical glucocorticoids were discovered to be the most effective therapies for canine atopic dermatitis. For the prevention of acute flares, prednisolone, methylprednisolone, and oral prednisone are commonly used. In comparison to other dosage types, the side effects are often low. During the forecast period, the Monoclonal Antibodies (MAbs) segment is anticipated to develop at a healthy pace. This treatment method is very recent, but it has shown to be very efficient. In 2016, Zoetis released the first MAb, which is provided to patients every 4 to 8 weeks and is said to alleviate itching instantly. More MAbs are currently being tested in clinical trials, with promising findings predicted in the near future.
The canine atopic dermatitis market is divided into three categories based on the mode of administration: injectable, topical, and oral. Because of its lower price, the oral segment had the highest market share in 2020. Furthermore, as opposed to injectable and topical forms, it is more convenient. The fact that dog owners will prescribe the medications themselves is stimulating demand. Because of its effectiveness and potency, the injectable segment is projected to rise substantially over the predicted timeframe. In the case of injectables, rapid onset of activity can be observed, which is predicted to drive demand in the immediate future. For improved outcomes, veterinarians are also recommending a mixture of oral and injectable treatment. The existence of a large product pipeline would accelerate the demand for the injectable segment.
The canine atopic dermatitis treatment market is classified into three groups based on distribution channels: e-commerce, retail, and veterinary hospitals/clinics. Due to increased product offerings, the retail sector led the market in 2020. The rise of retail pharmacy chains has had a substantial impact on the distribution channel segment's share. The implementation of digitalized technologies in retail pharmacies to minimize the risk of prescription errors is projected to fuel sales growth over the next few years. Furthermore, veterinarians have started to focus on general pharmacies to fill prescriptions for medications that are not available in veterinarian pharmacy, fueling business development. The rising popularity of e-commerce platforms is a key factor driving the e-commerce segment's profitability over the projected timeframe. The ease of shopping from websites with a large selection of products and comprehensive product descriptions is propelling the market forward. Furthermore, discounts on various platforms and a growing customer preference to purchase products online are projected to drive this segment's sales growth.
In 2020, North America led the market in the region, and this pattern is expected to continue throughout the projected timeframe. The rising occurrence of canine atopic dermatitis in pet dogs, new product releases, and increasing concerns among pet owners are all contributing to this development. Pet adoption is on the rise, which is driving demand growth even more. Besides that, global players are investing heavily in the manufacture of new drugs, which is projected to drive growth over the forecast period. Because of the vast number of pet dogs in this region, Latin America accounted for a significant portion of the total. Argentina and Brazil are in the top ten countries in the world with the most pets. Because of the rising adoption of pets and the increased incidence of infectious diseases in animals, the Asia Pacific region is projected to rise at a healthy rate over the projected timeframe. The likelihood of higher adoption of domestic animals grows as spending power rises, further enhancing future development opportunities. Continual improvements in healthcare facilities are also expected to provide the market with significant room for growth from 2021 to 2026.
Virbac, Bimeda, Inc., Novartis AG, Zoetis, AB Science, TORAY INDUSTRIES, INC., Vetoquinol S.A., Elanco, Ceva and Boehringer Ingelheim International GmbH are the major vendors competing in the canine atopic dermatitis market.
Please note: This is not an exhaustive list of companies profiled in the report.
Chapter 1 Methodology
1.1 Market Scope & Definitions
1.2 Estimates & Forecast Calculation
1.3 Historical Data Overview and Validation
1.4 Data Sources
1.4.1 Secondary
1.4.2 Primary
Chapter 2 Report Outlook
2.1 Canine Atopic Dermatitis Industry Overview, 2016-2026
2.1.1 Industry Overview
2.1.2 Product Overview
2.1.3 Mode of Administration Overview
2.1.4 Distribution Channel Overview
2.1.6 Regional Overview
Chapter 3 Canine Atopic Dermatitis Market Trends
3.1 Market Segmentation
3.2 Industry Background, 2016-2026
3.3 Market Key Trends
3.3.1 Positive Trends
3.3.1.1 Increasing prevalence of Canine Atopic Dermatitis
3.3.1.2 Rising research & development spending by key industry participants
3.3.2 Industry Challenges
3.3.2.1 Lack of awareness regarding pet diseases in developing nations
3.4 Prospective Growth Scenario
3.4.1 Product Growth Scenario
3.4.2 Mode of Administration Growth Scenario
3.4.3 Distribution Channel Growth Scenario
3.5 COVID-19 Influence over Industry Growth
3.6 Porter’s Analysis
3.7 PESTEL Analysis
3.8 Value Chain & Supply Chain Analysis
3.9 Regulatory Framework
3.9.1 North America
3.9.2 Europe
3.9.3 APAC
3.9.4 LATAM
3.9.5 MEA
3.10 Distribution Channel Overview
3.11 Market Share Analysis, 2020
3.11.1 Company Positioning Overview, 2020
Chapter 4 Canine Atopic Dermatitis Market, By Product
4.1 Product Outlook
4.2 Glucocorticoids
4.2.1 Market Size, By Region, 2016-2026 (USD Million)
4.3 Antihistamines
4.3.1 Market Size, By Region, 2016-2026 (USD Million)
4.4 Immunosuppressant,
4.4.1 Market Size, By Region, 2016-2026 (USD Million)
4.5 MAbs
4.5.1 Market Size, By Region, 2016-2026 (USD Million)
Chapter 5 Canine Atopic Dermatitis Market, By Mode of Administration
5.1 Mode of Administration Outlook
5.2 Topical
5.2.1 Market Size, By Region, 2016-2026 (USD Million)
5.3 Oral
5.3.1 Market Size, By Region, 2016-2026 (USD Million)
5.4 Injectable
5.4.1 Market Size, By Region, 2016-2026 (USD Million)
Chapter 6 Canine Atopic Dermatitis Market, By Distribution Channel
6.1 Veterinary Hospitals/Clinics
6.1.1 Market Size, By Region, 2016-2026 (USD Million)
6.2 Retail
6.2.1 Market Size, By Region, 2016-2026 (USD Million)
6.2 E-commerce
6.2.1 Market Size, By Region, 2016-2026 (USD Million)
Chapter 7 Canine Atopic Dermatitis Market, By Region
7.1 Regional outlook
7.2 North America
7.2.1 Market Size, By Country 2016-2026 (USD Million)
7.2.2 Market Size, By Product, 2016-2026 (USD Million)
7.2.3 Market Size, By Mode of Administration, 2016-2026 (USD Million)
7.2.4 Market Size, By Distribution Channel, 2016-2026 (USD Million)
7.2.6 U.S.
7.2.6.1 Market Size, By Product, 2016-2026 (USD Million)
7.2.4.2 Market Size, By Mode of Administration, 2016-2026 (USD Million)
7.2.4.3 Market Size, By Distribution Channel, 2016-2026 (USD Million)
7.2.7 Canada
7.2.7.1 Market Size, By Product, 2016-2026 (USD Million)
7.2.7.2 Market Size, By Mode of Administration, 2016-2026 (USD Million)
7.2.7.3 Market Size, By Distribution Channel, 2016-2026 (USD Million)
7.3 Europe
7.3.1 Market Size, By Country 2016-2026 (USD Million)
7.3.2 Market Size, By Product, 2016-2026 (USD Million)
7.3.3 Market Size, By Mode of Administration, 2016-2026 (USD Million)
7.3.4 Market Size, By Distribution Channel, 2016-2026 (USD Million)
7.3.6 Germany
7.3.6.1 Market Size, By Product, 2016-2026 (USD Million)
7.3.6.2 Market Size, By Mode of Administration, 2016-2026 (USD Million)
7.3.6.3 Market Size, By Distribution Channel, 2016-2026 (USD Million)
7.3.7 UK
7.3.7.1 Market Size, By Product, 2016-2026 (USD Million)
7.3.7.2 Market Size, By Mode of Administration, 2016-2026 (USD Million)
7.3.7.3 Market Size, By Distribution Channel, 2016-2026 (USD Million)
7.3.8 France
7.3.7.1 Market Size, By Product, 2016-2026 (USD Million)
7.3.7.2 Market Size, By Mode of Administration, 2016-2026 (USD Million)
7.3.7.3 Market Size, By Distribution Channel, 2016-2026 (USD Million)
7.3.9 Italy
7.3.9.1 Market Size, By Product, 2016-2026 (USD Million)
7.3.9.2 Market Size, By Mode of Administration, 2016-2026 (USD Million)
7.3.9.3 Market Size, By Distribution Channel, 2016-2026 (USD Million)
7.3.10 Spain
7.3.10.1 Market Size, By Product, 2016-2026 (USD Million)
7.3.10.2 Market Size, By Mode of Administration, 2016-2026 (USD Million)
7.3.10.3 Market Size, By Distribution Channel, 2016-2026 (USD Million)
7.3.11 Russia
7.3.11.1 Market Size, By Product, 2016-2026 (USD Million)
7.3.11.2 Market Size, By Mode of Administration, 2016-2026 (USD Million)
7.3.11.3 Market Size, By Distribution Channel, 2016-2026 (USD Million)
7.4 Asia Pacific
7.4.1 Market Size, By Country 2016-2026 (USD Million)
7.4.2 Market Size, By Product, 2016-2026 (USD Million)
7.4.3 Market Size, By Mode of Administration, 2016-2026 (USD Million)
7.4.4 Market Size, By Distribution Channel, 2016-2026 (USD Million)
7.4.6 China
7.4.6.1 Market Size, By Product, 2016-2026 (USD Million)
7.4.6.2 Market Size, By Mode of Administration, 2016-2026 (USD Million)
7.4.6.3 Market Size, By Distribution Channel, 2016-2026 (USD Million)
7.4.7 India
7.4.7.1 Market Size, By Product, 2016-2026 (USD Million)
7.4.7.2 Market Size, By Mode of Administration, 2016-2026 (USD Million)
7.4.7.3 Market Size, By Distribution Channel, 2016-2026 (USD Million)
7.4.8 Japan
7.4.7.1 Market Size, By Product, 2016-2026 (USD Million)
7.4.7.2 Market Size, By Mode of Administration, 2016-2026 (USD Million)
7.4.7.3 Market Size, By Distribution Channel, 2016-2026 (USD Million)
7.4.9 Australia
7.4.9.1 Market Size, By Product, 2016-2026 (USD Million)
7.4.9.2 Market size, By Mode of Administration, 2016-2026 (USD Million)
7.4.9.3 Market Size, By Distribution Channel, 2016-2026 (USD Million)
7.4.10 South Korea
7.4.10.1 Market Size, By Product, 2016-2026 (USD Million)
7.4.10.2 Market Size, By Mode of Administration, 2016-2026 (USD Million)
7.4.10.3 Market Size, By Distribution Channel, 2016-2026 (USD Million)
7.5 Latin America
7.5.1 Market Size, By Country 2016-2026 (USD Million)
7.5.2 Market Size, By Product, 2016-2026 (USD Million)
7.5.3 Market Size, By Mode of Administration, 2016-2026 (USD Million)
7.5.4 Market Size, By Distribution Channel, 2016-2026 (USD Million)
7.5.6 Brazil
7.5.6.1 Market Size, By Product, 2016-2026 (USD Million)
7.5.6.2 Market Size, By Mode of Administration, 2016-2026 (USD Million)
7.5.6.3 Market Size, By Distribution Channel, 2016-2026 (USD Million)
7.5.7 Mexico
7.5.7.1 Market Size, By Product, 2016-2026 (USD Million)
7.5.7.2 Market Size, By Mode of Administration, 2016-2026 (USD Million)
7.5.7.3 Market Size, By Distribution Channel, 2016-2026 (USD Million)
7.5.8 Argentina
7.5.7.1 Market Size, By Product, 2016-2026 (USD Million)
7.5.7.2 Market Size, By Mode of Administration, 2016-2026 (USD Million)
7.5.7.3 Market Size, By Distribution Channel, 2016-2026 (USD Million)
7.6 MEA
7.6.1 Market Size, By Country 2016-2026 (USD Million)
7.6.2 Market Size, By Product, 2016-2026 (USD Million)
7.6.3 Market Size, By Mode of Administration, 2016-2026 (USD Million)
7.6.4 Market Size, By Distribution Channel, 2016-2026 (USD Million)
7.6.6 Saudi Arabia
7.6.6.1 Market Size, By Product, 2016-2026 (USD Million)
7.6.6.2 Market Size, By Mode of Administration, 2016-2026 (USD Million)
7.6.6.3 Market Size, By Distribution Channel, 2016-2026 (USD Million)
7.6.7 UAE
7.6.7.1 Market Size, By Product, 2016-2026 (USD Million)
7.6.7.2 Market Size, By Mode of Administration, 2016-2026 (USD Million)
7.6.7.3 Market Size, By Distribution Channel, 2016-2026 (USD Million)
7.6.8 South Africa
7.6.7.1 Market Size, By Product, 2016-2026 (USD Million)
7.6.7.2 Market Size, By Mode of Administration, 2016-2026 (USD Million)
7.6.7.3 Market Size, By Distribution Channel, 2016-2026 (USD Million)
Chapter 8 Company Landscape
8.1 Competitive Analysis, 2020
8.2 Bimeda, Inc
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Strategic Positioning
8.2.4 Info Graphic Analysis
8.3 Virbac
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Strategic Positioning
8.3.4 Info Graphic Analysis
8.4 Novartis AG
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Strategic Positioning
8.4.4 Info Graphic Analysis
8.5 AB Science
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Strategic Positioning
8.5.4 Info Graphic Analysis
8.6 Zoetis
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Strategic Positioning
8.6.4 Info Graphic Analysis
8.7 TORAY INDUSTRIES, INC.
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Strategic Positioning
8.7.4 Info Graphic Analysis
8.8 Elanco
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Strategic Positioning
8.8.4 Info Graphic Analysis
8.9 Boehringer Ingelheim International GmbH
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Strategic Positioning
8.8.4 Info Graphic Analysis
8.10 Ceva
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Strategic Positioning
8.10.4 Info Graphic Analysis
8.11 Other Companies
8.11.1 Company Overview
8.11.2 Financial Analysis
8.11.3 Strategic Positioning
8.11.4 Info Graphic Analysis
The Global Canine Atopic Dermatitis Market has been studied from the year 2019 till 2026. However, the CAGR provided in the report is from the year 2021 to 2026. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process.
The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply-side analysis for the Canine Atopic Dermatitis Market.
The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, distributors, and end-use product manufacturers.
Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: market attractiveness, current & future market trends, market share analysis, SWOT analysis of the company and customer analytics.
Frequently Asked Questions
Tailor made solutions just for you
80% of our clients seek made-to-order reports. How do you want us to tailor yours?
OUR CLIENTS